Neoadjuvant FOLFIRINOX followed by Chemoradiotherapy for Middle and Lower Rectal Cancer
| Autor: | Saeed Shaaban, Rabab Abdel Moneim, Moustafa Aldaly, Mamdouh El-Sherbiny, Amr Sakr |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Adult Male medicine.medical_specialty Colorectal cancer FOLFIRINOX Leucovorin Irinotecan Deoxycytidine 03 medical and health sciences Young Adult 0302 clinical medicine FOLFOX Median follow-up Antineoplastic Combined Chemotherapy Protocols medicine Humans Neoplasm Invasiveness Prospective Studies Rectal cancer business.industry Rectal Neoplasms sphincter preservation Combination chemotherapy General Medicine Chemoradiotherapy Middle Aged medicine.disease Prognosis Neoadjuvant Therapy Oxaliplatin Surgery Survival Rate 030104 developmental biology 030220 oncology & carcinogenesis Lymphatic Metastasis Female Fluorouracil Neoplasm Recurrence Local business medicine.drug Follow-Up Studies Research Article neoadjuvant chemotherapy |
| Zdroj: | Asian Pacific Journal of Cancer Prevention : APJCP |
| ISSN: | 2476-762X |
| Popis: | Objective Neoadjuvant concomitant chemoradiotherapy followed by surgical resection is the standard of care in the treatment of rectal cancer. We are investigating the value of adding combination chemotherapy oxaliplatin, irinotecan, leucovorin and fluorouracil (FOLFIRINOX) before neoadjuvant chemoradiotherapy. Methods Forty-one patients with middle and lower rectal cancer were included. FOLFORINOX were given every 2 weeks over 2 months (4 cycles) followed by concomitant chemoradiotherapy (CRT). Surgery was done 6-8 weeks after CRT and then adjuvant 4 months of FOLFOX or XELOX were given. The primary end point was sphincter preservation rate. Results All patients received the four cycles of neoadjuvant chemotherapy FOLFORINOX, 38 patients completed CRT and only 29 patients underwent surgery. 32 patients were available for assessment (29 patients who underwent surgery and three patients who refuse surgery because of no evidence of disease by endoscopy, imaging and biopsy). Sphincter preservation was achieved in twenty-one patients (51.2%). Pathological complete response rate was 24.1%. After a median follow up of 24 months. Median PFS was 20 months and 2-years PFS was 62.3%. The median overall survival of all patients was not reached, while 2-years OS was 76.5%. Conclusion Neoadjuvant FOLFIRINOX followed by CRT for middle and lower rectal cancer is feasible, tolerable with satisfactory sphincter preservation rate. . |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|